Recent Finacing
Recent Raise
F2G is a clinical-stage biopharmaceutical company that discovers and develops orotomide antifungals targeting DHODH, advancing oral lead candidate olorofim in Phase 2b for invasive and rare mold infections.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at F2G.
